Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Isofol Medical AB ( (SE:ISOFOL) ) has issued an update.
Isofol Medical AB has initiated a clinical phase Ib/II study for its drug candidate arfolitixorin, aimed at treating metastatic colorectal cancer. The study, conducted at Charité – Universitätsmedizin Berlin, seeks to optimize the dosing regimen to improve efficacy, marking a significant step towards bringing arfolitixorin to market and potentially improving outcomes for patients with advanced cancers.
More about Isofol Medical AB
Isofol Medical AB is a research-based biotechnology company focused on improving the prognosis for patients with severe forms of cancer. The company is developing a drug candidate, arfolitixorin, to enhance the efficacy of first-line standard treatments for solid tumors, with a current focus on colorectal cancer. Isofol Medical AB is listed on Nasdaq Stockholm.
YTD Price Performance: -15.76%
Technical Sentiment Signal: Buy
Current Market Cap: €27.86M
For a thorough assessment of ISOFOL stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue